10-K/A: Allogene Therapeutics Restates Financials Following SEC Comment on Joint Venture Accounting

Allogene Therapeutics has amended its annual report to restate financial statements due to an SEC comment regarding accounting for a joint venture, impacting revenue and expense recognition.

Summary

• Allogene Therapeutics has filed an amended annual report to restate its financial statements for the years ended December 31, 2022, 2021 and 2020.
• The restatement was prompted by an SEC comment letter regarding the accounting treatment of Allogene Overland Biopharm, a joint venture with Overland Pharmaceuticals.
• The company initially recorded its equity investment in Allogene Overland at zero, but has now restated to reflect the fair value of the Seed Preferred Shares received as partial consideration for a license agreement.
• This restatement resulted in additional revenues of $114.1 million under Collaboration revenue related party in 2021.
• The company also recorded a basis difference of $67.5 million as Other expenses in 2020, representing the difference between the fair value of the Seed Preferred Shares and the company's underlying equity in net assets of Allogene Overland.
• The restatement is non-cash in nature and did not impact cash, cash equivalents, or marketable investments.
• Management has concluded that the company's disclosure controls and procedures were not effective at the reasonable assurance level and that the company's internal control over financial reporting was not effective as of the end of each of the periods covered by the restatement.
• A material weakness in internal control over financial reporting was identified with respect to the technical accounting analysis of significant non-routine transactions.

Sentiment

Score: 3

Explanation: The document reveals significant accounting issues and a material weakness in internal controls, which is a negative signal for investors. The restatement and the identified weakness raise concerns about the reliability of the company's financial reporting.

Negatives

• The company's disclosure controls and procedures were deemed ineffective at a reasonable assurance level.
• The company's internal control over financial reporting was deemed ineffective as of the end of each of the periods covered by the restatement.
• A material weakness in internal control over financial reporting was identified.

Risks

• The company has identified a material weakness in its internal control over financial reporting, which could adversely affect its ability to report financial results accurately and in a timely manner.
• The company's disclosure controls and procedures were not effective at a reasonable assurance level.
• The company's internal control over financial reporting was not effective as of the end of each of the periods covered by the restatement.
• The company may face challenges in remediating the identified material weakness and may need to take additional measures to address the issue.

Future Outlook

Forward-looking statements made in the original report have not been revised to reflect events, results or developments that occurred or facts that became known to the company after the date of the original report.

Management Comments

• Management has concluded that the company's disclosure controls and procedures were not effective at the reasonable assurance level.
• Management has concluded that the company's internal control over financial reporting was not effective as of the end of each of the periods covered by the restatement.

Industry Context

The restatement highlights the complexities in accounting for joint ventures, particularly in the biotechnology industry where collaborations and partnerships are common. It also underscores the importance of robust internal controls and compliance with SEC regulations.

Comparison to Industry Standards

• The restatement of financial statements due to SEC comments is not uncommon in the biotechnology industry, particularly for companies with complex collaborations and joint ventures.
• Companies like Kite Pharma and Novartis, which have developed autologous CAR T-cell therapies, have also faced scrutiny and adjustments in their financial reporting, although not directly related to joint venture accounting.
• The identification of a material weakness in internal control over financial reporting is a serious matter that requires prompt remediation, and is not uncommon for companies in the biotechnology industry, especially those that are rapidly growing or have complex transactions.
• Comparable companies such as CRISPR Therapeutics and Fate Therapeutics have also faced challenges in their financial reporting and internal controls, highlighting the complexities of the biotechnology sector.

Related Party Transactions

• The company has a License Agreement with Allogene Overland Biopharm, a joint venture with Overland Pharmaceuticals.
• The company has a consulting agreement with Two River Consulting LLC, a firm affiliated with the company's President and Chief Executive Officer, the company's Executive Chair of the board of directors, and a director of the company.
• The company has a consulting agreement with Bellco Capital LLC, a firm affiliated with the company's executive chair.
• The company has a sublease agreement with Bellco Capital Advisors Inc., a firm affiliated with the company's executive chair.

Stakeholder Impact

• Shareholders may be concerned about the reliability of the company's financial reporting due to the restatement and identified material weakness.
• Employees may be affected by the company's efforts to remediate the material weakness, which may involve changes to processes and controls.
• Creditors may be concerned about the company's financial stability and ability to meet its obligations.
• Customers and partners may be concerned about the company's ability to execute on its business plans.

Next Steps

• The company plans to devote significant effort and resources to the remediation and improvement of its internal control over financial reporting.
• The company plans to enhance its processes to better evaluate its research and understanding of the nuances of the complex accounting standards that apply to its financial statements.
• The company plans to retain third-party subject matter experts with significant relevant experience to help with accounting treatment of significant non-routine transactions.

Key Dates

Keywords

restatement, financial statements, Allogene Therapeutics, joint venture, Allogene Overland, SEC, internal control, material weakness, accounting, revenue recognition